Jazz Closes $1.25B Exchangeable Notes Offering, Repurchases $225M in Shares
JAZZ has more than doubled off its 52-week low of $123.88.
Summary
Jazz Pharmaceuticals closed a $1.25B exchangeable notes offering with a 1.875% coupon and a 42.5% conversion premium, while repurchasing $225M of its own shares.
Key Events · Financing and Capital Events · JAZZ
-
Notes Offering Closed
Jazz Investments I Limited completed a $1.25B offering of 1.875% exchangeable senior notes due 2032, including full exercise of the $150M initial purchaser option.
-
Net Proceeds
Net proceeds are approximately $1,226.4M after discounts, commissions, and estimated expenses, to be used for general corporate purposes.
-
Concurrent Share Repurchase
Jazz repurchased $225M of ordinary shares at $249.29 per share, funded with existing cash, reducing the remaining authorization under its July 2024 repurchase program.
-
Exchange Terms
Initial exchange rate of 2.8150 shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share, a 42.5% premium to the August 26, 2026 closing price.
Analysis · JAZZ · Life Sciences
Jazz Pharmaceuticals completed a $1.25 billion exchangeable senior notes offering, upsized from the initially announced $1.0 billion, with net proceeds of approximately $1.23 billion. The notes carry a 1.875% coupon and an initial exchange price of $355.24 per share, a 42.5% premium to the last reported sale price on August 26, 2026. Concurrently, the company repurchased $225 million of its ordinary shares at $249.29 per share, using existing cash. This financing strengthens the balance sheet for general corporate purposes while the concurrent buyback partially offsets potential dilution from the exchangeable notes.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1939 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAZZ was trading at $250.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.3B. The 52-week trading range was $123.88 to $266.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.